Pelareorep

Promising Developments Announced Ahead of 2023 ASCO Annual Meeting's Oral Presentations

Retrieved on: 
Friday, May 26, 2023
Optimism, Senior, Survival, Merck Group, Doctor of Philosophy, IMGN, GILD, MD, NUALS Arts and Literary Annual Meet, Patient, Sacituzumab govitecan, SVP, News, Business development, Brain, DPD, Hope, Mirvetuximab soravtansine, B-cell lymphoma, Gilead, Bortezomib, ONC, Randomness, TSX, Entrepreneurship, Safety, Axicabtagene ciloleucel, Gilead Sciences, Oncolytics Biotech, Neuro-Oncology (journal), CDK, Overalls, Cancer, Lung cancer, ImmunoGen, CBR, National Cancer Institute, Lymphoma, Daratumumab, ORR, Glioma, Pfizer, Progression-free survival, Paclitaxel, PVD, Dexamethasone, Fast track (FDA), ASCO, American Society of Clinical Oncology, Mantle cell lymphoma, Pelareorep, EHA, Multiple myeloma, Metastatic breast cancer, Society, Female, Breast cancer, Pharmaceutical industry, Birth control, Vaccine

VANCOUVER, B.C., May 26, 2023 /PRNewswire/ -- USA News Group  -  The world's biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with in-person attendance back in full swing and already 40,000 people registered by mid-May. Much like other years, there's plenty of optimism ahead for the findings and intriguing data set to be presented, with oral presentations from some of the biotech sector's finest and up-and-comers, including from Gilead Sciences, Inc. (NASDAQ:GILD), ImmunoGen, Inc. (NASDAQ:IMGN), Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN), Legend Biotech Corporation (NASDAQ:LEGN), and Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC).

Key Points: 
  • According to the National Cancer Institute, HR+/HER2- is the most common cancer subtype, accounting for roughly 69% of all female breast cancer cases.
  • It's worth noting that Oncolytics has stated that it will also be presenting updated data from May 2023 at the oral presentation.
  • Additional data will be presented during the 2023 ASCO oral presentation.
  • Bringing in eight presentations to ASCO and EHA 2023 Annual Meetings, Legend Biotech Corporation (NASDAQ:LEGN) is set to deliver new and updated data from the CARTITUDE Clinical Development Program.

Promising Developments Announced Ahead of 2023 ASCO Annual Meeting's Oral Presentations

Retrieved on: 
Friday, May 26, 2023
Optimism, Senior, Survival, Merck Group, Doctor of Philosophy, IMGN, GILD, MD, NUALS Arts and Literary Annual Meet, Patient, Sacituzumab govitecan, SVP, News, Business development, Brain, DPD, Hope, Mirvetuximab soravtansine, B-cell lymphoma, Gilead, Bortezomib, ONC, Randomness, TSX, Entrepreneurship, Safety, Axicabtagene ciloleucel, Gilead Sciences, Oncolytics Biotech, Neuro-Oncology (journal), CDK, Overalls, Cancer, Lung cancer, ImmunoGen, CBR, National Cancer Institute, Lymphoma, Daratumumab, ORR, Glioma, Pfizer, Progression-free survival, Paclitaxel, PVD, Dexamethasone, Fast track (FDA), ASCO, American Society of Clinical Oncology, Mantle cell lymphoma, Pelareorep, EHA, Multiple myeloma, Metastatic breast cancer, Society, Female, Breast cancer, Pharmaceutical industry, Birth control, Vaccine

VANCOUVER, B.C., May 26, 2023 /PRNewswire/ -- USA News Group  -  The world's biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with in-person attendance back in full swing and already 40,000 people registered by mid-May. Much like other years, there's plenty of optimism ahead for the findings and intriguing data set to be presented, with oral presentations from some of the biotech sector's finest and up-and-comers, including from Gilead Sciences, Inc. (NASDAQ:GILD), ImmunoGen, Inc. (NASDAQ:IMGN), Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN), Legend Biotech Corporation (NASDAQ:LEGN), and Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC).

Key Points: 
  • According to the National Cancer Institute, HR+/HER2- is the most common cancer subtype, accounting for roughly 69% of all female breast cancer cases.
  • It's worth noting that Oncolytics has stated that it will also be presenting updated data from May 2023 at the oral presentation.
  • Additional data will be presented during the 2023 ASCO oral presentation.
  • Bringing in eight presentations to ASCO and EHA 2023 Annual Meetings, Legend Biotech Corporation (NASDAQ:LEGN) is set to deliver new and updated data from the CARTITUDE Clinical Development Program.

Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract

Retrieved on: 
Thursday, May 25, 2023
Progression-free survival, CDK, Survival, AB, Paclitaxel, Merck Group, ASCO, ONC, American Society of Clinical Oncology, Patient, SAN, Pelareorep, Annual general meeting, TSX, Society, ORR, Pfizer, Breast cancer, Birth control, Satellite navigation device, Pharmaceutical industry

SAN DIEGO and CALGARY, AB, May 25, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced positive results from BRACELET-1, a randomized phase 2 trial in HR+/HER2- metastatic breast cancer. The results are published in an abstract accepted for an oral presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 2 – 6, 2023 in Chicago, Illinois and online. The abstract is available on the ASCO Annual Meeting website.

Key Points: 
  • The abstract is available on the ASCO Annual Meeting website.
  • All participants enrolled in the trial previously progressed on at least one hormone-based therapy with a CDK 4/6 inhibitor.
  • This cohort also reported median progression-free survival (mPFS) of 9.6 months vs. 6.4 months as of the cut-off date.
  • Updated results as of a May cut-off date will be featured in an oral presentation at the ASCO meeting on June 3, 2023.

Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract

Retrieved on: 
Thursday, May 25, 2023
Progression-free survival, CDK, Survival, AB, Paclitaxel, Merck Group, ASCO, ONC, American Society of Clinical Oncology, Patient, SAN, Pelareorep, Annual general meeting, TSX, Society, ORR, Pfizer, Breast cancer, Birth control, Satellite navigation device, Pharmaceutical industry

SAN DIEGO, and CALGARY, AB , May 25, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced positive results from BRACELET-1, a randomized phase 2 trial in HR+/HER2- metastatic breast cancer. The results are published in an abstract accepted for an oral presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 2 – 6, 2023 in Chicago, Illinois and online. The abstract is available on the ASCO Annual Meeting website.

Key Points: 
  • The abstract is available on the ASCO Annual Meeting website.
  • All participants enrolled in the trial previously progressed on at least one hormone-based therapy with a CDK 4/6 inhibitor.
  • This cohort also reported median progression-free survival (mPFS) of 9.6 months vs. 6.4 months as of the cut-off date.
  • Updated results as of a May cut-off date will be featured in an oral presentation at the ASCO meeting on June 3, 2023.

Oncolytics Biotech® Reports First Quarter 2023 Financial Results and Operational Highlights

Retrieved on: 
Friday, May 5, 2023
PDAC, Pancreatic cancer, KOL, International, Oncolytics Biotech, Progression-free survival, Survival, AB, Paclitaxel, Breast, Prognosis, Research, Immunotherapy, ASCO, CAR, ONC, Data, Patient, Risk, Pelareorep, Science Translational Medicine, STM, TSX, Neoplasm, Poster, LINK, PR, Breast cancer, Cryptocurrency, Pharmaceutical industry, Medical imaging, Satellite navigation device

SAN DIEGO, Calif. and CALGARY, AB, May 5, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the first quarter ended March 31, 2023. All dollar amounts are expressed in Canadian currency unless otherwise noted.

Key Points: 
  • ET
    SAN DIEGO, Calif. and CALGARY, AB, May 5, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the first quarter ended March 31, 2023.
  • The net loss for the first quarter of 2023 was $6.4 million, compared to a net loss of $6.8 million for the first quarter of 2022.
  • General and administrative expenses for the first quarter of 2023 were $3.2 million, compared to $2.6 million for the first quarter of 2022.
  • Research and development expenses for the first quarter of 2023 were $3.5 million, compared to $3.7 million for the first quarter of 2022.

Oncolytics Biotech® Reports First Quarter 2023 Financial Results and Operational Highlights

Retrieved on: 
Friday, May 5, 2023
PDAC, Pancreatic cancer, KOL, International, Oncolytics Biotech, Progression-free survival, Survival, AB, Paclitaxel, Breast, Prognosis, Research, Immunotherapy, ASCO, CAR, ONC, Data, Patient, Risk, Pelareorep, Science Translational Medicine, STM, TSX, Neoplasm, Poster, LINK, PR, Breast cancer, Cryptocurrency, Pharmaceutical industry, Medical imaging, Satellite navigation device

SAN DIEGO, Calif. and CALGARY, AB, May 5, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the first quarter ended March 31, 2023. All dollar amounts are expressed in Canadian currency unless otherwise noted.

Key Points: 
  • ET
    SAN DIEGO, Calif. and CALGARY, AB, May 5, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the first quarter ended March 31, 2023.
  • The net loss for the first quarter of 2023 was $6.4 million, compared to a net loss of $6.8 million for the first quarter of 2022.
  • General and administrative expenses for the first quarter of 2023 were $3.2 million, compared to $2.6 million for the first quarter of 2022.
  • Research and development expenses for the first quarter of 2023 were $3.5 million, compared to $3.7 million for the first quarter of 2022.

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

Retrieved on: 
Friday, March 3, 2023
FDA, Immunotherapy, SITC, International, Pancreatic cancer, Clinical trial, Accelerated approval (FDA), Progression-free survival, Breast, Pelareorep, TSX, Breast cancer, Pulmonary toxicity, Food, Oncolytics Biotech, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ORR, Growth, Research, ONC, Safety, CAR, Society, Fast Track, Annual general meeting, PR, Society for Immunotherapy of Cancer, LINK, Priority review, Paclitaxel, Patient, Survival, Cryptocurrency, Medical imaging, Pharmaceutical industry, Video game, Satellite navigation device, PDAC

ET

Key Points: 
  • ET
    SAN DIEGO and CALGARY, Alberta, March 3, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the fourth quarter and full year ended December 31, 2022.
  • The net loss for the fourth quarter of 2022 was $8.6 million, compared to a net loss of $7.8 million in the fourth quarter of 2021.
  • The basic and diluted loss per share was $0.14 in the fourth quarter of 2022, compared to a basic and diluted loss per share of $0.14 in the fourth quarter of 2021.
  • General and administrative expenses for the fourth quarter of 2022 were $3.7 million and $11.5 million for the full year 2022, compared to $3.8 million for the fourth quarter of 2021 and $13.3 million for the full year 2021.

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

Retrieved on: 
Friday, March 3, 2023
FDA, Immunotherapy, SITC, International, Pancreatic cancer, Clinical trial, Accelerated approval (FDA), Progression-free survival, Breast, Pelareorep, TSX, Breast cancer, Pulmonary toxicity, Food, Oncolytics Biotech, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ORR, Growth, Research, ONC, Safety, CAR, Society, Fast Track, Annual general meeting, PR, Society for Immunotherapy of Cancer, LINK, Priority review, Paclitaxel, Patient, Survival, Cryptocurrency, Medical imaging, Pharmaceutical industry, Video game, Satellite navigation device, PDAC

ET

Key Points: 
  • ET
    SAN DIEGO and CALGARY, Alberta, March 3, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the fourth quarter and full year ended December 31, 2022.
  • The net loss for the fourth quarter of 2022 was $8.6 million, compared to a net loss of $7.8 million in the fourth quarter of 2021.
  • The basic and diluted loss per share was $0.14 in the fourth quarter of 2022, compared to a basic and diluted loss per share of $0.14 in the fourth quarter of 2021.
  • General and administrative expenses for the fourth quarter of 2022 were $3.7 million and $11.5 million for the full year 2022, compared to $3.8 million for the fourth quarter of 2021 and $13.3 million for the full year 2021.

iOnctura initiates Phase Ib pancreatic cancer trial of next-generation autotaxin inhibitor IOA-289

Retrieved on: 
Thursday, December 8, 2022
Liver, PDAC, Extracellular matrix, Patient, Neoplasm, Pancreatic cancer, ATX, Diagnosis, Tumor microenvironment, University of Glasgow, Phases of clinical research, Pelareorep, University of Alberta, Safety, Cancer, Drug resistance, Doctor of Philosophy, University of Siena, Drug development, Collagen, University of Verona, Lymphocyte, Immune system, University, Pharmaceutical industry, Medical imaging, Biochemistry

“We are excited to progress clinical development of our autotaxin (ATX) inhibitor IOA-289, the second most advanced product in our pipeline,” said Catherine Pickering, PhD, CEO of iOnctura.

Key Points: 
  • “We are excited to progress clinical development of our autotaxin (ATX) inhibitor IOA-289, the second most advanced product in our pipeline,” said Catherine Pickering, PhD, CEO of iOnctura.
  • Fibrotic cancers, including pancreatic cancer, are characterized by the deposition of thick layers of extracellular matrix containing collagen fibers and pro-tumorigenic factors.
  • Pancreatic cancer (PDAC): Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer accounting for approximately 90% of cases.
  • There are over 50,000 diagnoses of pancreatic cancer each year in the United States and over 65,000 in the EU5.

Oncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Canc

Retrieved on: 
Thursday, December 8, 2022
ONC, Biotechnology, Travel, PIK3CA, Global Vision, PR, Poster, Paclitaxel, Patient, Partnership, Șaeș, EP4, SD, Research, PFS, Progression-free survival, Roche, Breast cancer, Neoplasm, REO, Cancer, LINK, COVID-19, Survival, Clinical trial, Lymphatic system, AB, Safety, TSX, SAN, Pulmonary toxicity, Regulation, Pancreatic cancer, Phenotype, Medical imaging, Pharmaceutical industry, Vaccine, Pelareorep, Oncolytics Biotech

SAN DIEGO and CALGARY, AB, Dec. 8, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc.'s (NASDAQ: ONCY) (TSX: ONC) Chinese partner Adlai Nortye today announced interim results from a multicenter, single-arm bridging clinical trial to evaluate the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced/metastatic HR+/HER2- breast cancer. The data were featured in a poster presented yesterday at the San Antonio Breast Cancer Symposium (SABCS), which is being held at the Henry B. González Convention Center in San Antonio, Texas through December 10, 2022.

Key Points: 
  • 's (NASDAQ: ONCY) (TSX: ONC) Chinese partner Adlai Nortye today announced interim results from a multicenter, single-arm bridging clinical trial to evaluate the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced/metastatic HR+/HER2- breast cancer.
  • One patient achieving a PR at week 8 has maintained the PR through week 48 and remains on study.
  • The studied combination has been well tolerated, with no dose-limiting toxicities or serious adverse events (SAEs) reported to date.
  • "With no SAEs reported, the data suggests the favorable safety and potent anti-cancer activity displayed by the studied combination in North American HR+/HER2- breast cancer patients extends to the Chinese population.